Metabolic · ~3 min read
Semaglutide: What It Is, How It Works & What the Research Shows
Overview
Semaglutide is a GLP-1 receptor agonist. It increases glucose-dependent insulin release, slows gastric emptying and reduces appetite through signaling in the brain. It is FDA-approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management. In the STEP 1 trial, 2.4 mg weekly produced about 14.9% mean weight loss over 68 weeks, and the SELECT trial showed a 20% reduction in major cardiovascular events in people with obesity and heart disease. Its roughly 7-day half-life supports once-weekly dosing.
Why researchers study it
Weight management
FDA-approved as Wegovy; STEP trials showed about 15% average weight loss.
Type 2 diabetes
Lowers blood sugar and HbA1c through GLP-1 signaling (Ozempic, Rybelsus).
Heart health
The SELECT trial showed 20% fewer major cardiovascular events.
Liver & kidney
Studied in fatty liver disease (MASH) and diabetic kidney disease.
How it works
Activates GLP-1 receptors, increasing glucose-dependent insulin secretion and reducing glucagon secretion. Effects on appetite and gastric emptying contribute to its metabolic actions.
Adamantane & the blood–brain barrier
Chemically attaching an adamantane group to a peptide can increase its lipid (fat) solubility. Researchers hypothesize that this modification may help certain compounds cross the tightly regulated blood–brain barrier. The effect depends on the specific modified molecule; greater lipid solubility alone does not establish brain delivery or clinical benefit. This does not apply automatically to the unmodified peptide and is not a reconstitution additive.
What the research shows
- STEP 1 evaluated body-weight reduction in adults with overweight or obesity without diabetes.
- Licensed semaglutide medicines have indication-specific evidence for weight management and type 2 diabetes; injectable and oral formulations have different labeling.
Typical protocol
Reconstitute a 10 mg vial with 1 mL bacteriostatic water for 10 mg/mL. Typical range: 0.25–2.4 mg 1x daily · 1–2x weekly (split dose), As long as needed.
Common stacks
- Semaglutide + Cagrilintide — A randomized phase 1b study investigated concomitant administration for weight management.
Potential benefits & side effects
Potential benefits
- Significant reduction in appetite and food noise
- Clinically meaningful weight loss
- Improved blood sugar and insulin sensitivity
- Improvements in blood pressure, lipids and liver fat
Side effects
- Nausea, vomiting, diarrhea or constipation (most common, usually during dose increases)
- Reduced appetite to the point of under-eating
- Fatigue and occasional headache
- Increased heart rate (especially triple/glucagon agonists)
- Rare: gallbladder problems or pancreatitis — seek care for severe abdominal pain
Lifestyle factors
- Protein: aim for adequate protein (about 0.7–1 g per lb of goal body weight) to preserve muscle during weight loss.
- Resistance training: lift 2–4x per week to protect lean mass.
- Hydration & fiber: drink plenty of water and eat fiber to reduce constipation and nausea.
- Meal size: eat smaller meals and stop at fullness; greasy, heavy meals worsen GI side effects.
- Titrate slowly: stay at a dose until side effects settle before increasing.